Know Your Myeloma Immunotherapy: Bispecific Antibody Review
A myeloma specialist, Dr. Hultcrantz treats patients and conducts research on cutting-edge immunotherapies, which are a promising category of myeloma therapy. Monoclonal antibodies are changing treatment paradigms and the use of CAR T is expected to grow dramatically over the next few years. Bi-specifics are a new type of immunotherapy—one approved and many more in phase 1 and 2 studies—that promise to add more options for patients with potentially greater ease and increased survival rates. Learn more about bi-specifics in Dr. Hultcrantz’s presentation: Who are they for? What are clinical trials studying? And much, much more. Register now and come with your questions!
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Malin Hultcrantz, MD, PhD
Malin Hultcrantz, MD, PhD, is a board-certified hematologist who specializes in the treatment of multiple myeloma and related plasma cell disorders including the precursor disorders monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma at the Memorial Sloan Kettering Cancer Center. She is focused on further optimizing treatment strategies for people with multiple myeloma, and offers a variety of modern treatments including clinic trials and novel immunotherapies. She is also working on measures to continue to improve patients’ quality of life while receiving treatment for multiple myeloma. Additionally, she has a particular interest in studying mechanisms and markers of progression from precursor disease to multiple myeloma. As part of this effort, she is working with her colleagues to develop targeted genomic tests for disease characterization and measurement of minimal residual disease. Better understanding of disease biology allows for better risk stratification and personalized treatment including early treatment for patients with high-risk precursor disease. In 2015, Dr. Hultcrantz received the Research Fellow Award, Multiple Myeloma Research Foundation and the International Postdoc Award, Swedish Research Council. Dr. Hultcrantz is fluent in Swedish and English.